Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, reported today that the sales of the antifungal Cresemba® (isavuconazole) in Japan exceeded the threshold triggering the first sales milestone payment from its partner Asahi Kasei Pharma (AKP), amounting to approximately CHF 1.2 million. David Veitch, Chief Executive Officer of Basilea, said: “Japan is a key market

Agreement drives continued patient access to four important therapies in Japan and Korea Strengthens Essential Pharma and Clinigen’s combined market presence in the JAPAC region 6th February 2025 – Essential Pharma (“Essential” or “the Company”), an international specialty pharma group focused on ensuring that patients have access to low volume, clinically differentiated, niche pharmaceutical products across key therapeutic areas, and Clinigen, the global specialty pharmaceutical services group,

Feb. 05, 2025 -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical”), a clinical-stage biotechnology company advancing regenerative medicine solutions, today announced an expanded agreement with Greenstone Biosciences Inc. (“Greenstone”) to leverage Artificial Intelligence (AI) in further developing its human induced pluripotent stem cell (iPSC) platform for diabetes treatment.This strategic collaboration extends the progress made on Creative Medical’s proprietary hy

February 4, 2025 – Revium Rx (formerly Revium Recovery Inc., OTC: RVRC) has completed the strategic acquisition of LipoVation Ltd., an Israeli development-stage company specializing in lipid-based nano/micro particle medicines. This acquisition marks a significant shift in Revium Rx’s focus toward nanoparticle-based therapeutics, positioning the company at the forefront of advanced drug delivery technologies for hard-to-treat diseases. LipoVation’s core technology was conceptualized by Prof. Ye

Jan. 28, 2025 -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company developing innovative cancer therapies, today announced that it has entered into definitive agreements to sell a portion of its Series A-1 Preferred Shares of SEED Therapeutics Inc. (“SEED”), a biotechnology company focused on Targeted Protein Degradation (TPD) technology and a subsidiary of the Company, for gross proceeds of approximately $35.4 million. Upon c

January 28, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, reported today that the sales in 2024 of the antifungal Cresemba® (isavuconazole) and the antibiotic Zevtera® (ceftobiprole) exceeded thresholds triggering sales milestone payments from distribution partners to Basilea, in the total amount of approximately CHF 2.2 million. For Cresemba, this compri

OSE Immunotherapeutics and Scienta Lab Establish Strategic Partnership to Leverage Artificial Intelligence in Precision Immunotherapy January 29, 2025 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) and Scienta Lab, a leader in Artificial Intelligence (AI)-driven precision immunology, announce a strategic collaboration to harness Scienta Lab’s advanced AI platform for modeling inflammatory diseases and identifying predictive biomarkers of efficacy for immunotherapies.

Jan. 28, 2025 -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the strengthening of its foothold throughout Europe and the Middle East through its partnership with IVY Diagnostics Srl (“IVY Diagnostics”). As a key distributor, IVY Diagnostics is playing an integral role in expanding the adoption of INBS' Intelligent Fingerprinting Drug Testing Solution across Eu

Study is the first randomized, controlled trial examining a vaccine’s effectiveness in controlling CMV in recipients of HSCT from vaccinated donors Encouraging pilot study results demonstrated the benefit of vaccinating donors with Triplex to convey protective CMV-specific T cell immunity to allogeneic HSCT recipients at risk for CMV reactivation Jan. 27, 2025 -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), and its majority-owned subsidiary, Helocyte, Inc. (“Helocyte”), today announced t

赛默飞将通过其 Accelerator™ 药物开发平台、360° CDMO 和 CRO 解决方案，于 2025 年上半年开始为 Lyndra 的口服周剂利培酮 (LYN-005) III 期关键安全性研究提供临床研究服务，并利用 Lyndra 的 LYNX® 药物递送平台进行长效口服药物的商业化生产。 2025 年 1 月 15 日上午 10:00 Lyndra Therapeutics 是一家开发长效口服药物、处于临床阶段的领先生物制药公司，于今日宣布与科学服务领域的世界领导者赛默飞世尔科技公司 (Thermo Fisher Scientific Inc.) 达成战略合作，赛默飞将在全球范围内为 Lyndra 的长效口服药物提供临床研究和商业化生产服务。 “赛默飞很荣幸能与 Lyndra 携手开发创新药物递送平台，我们非常期待向患者提供突破性的长效口服药物。” Lyndra 的长效口服药物包括主要的临床试验药物——口服周剂利培酮 (LYN-005) ，可通过单次口服给药维持一周或更长时间的疗效。LYN-005 在 III 期关键性 STARLYNG-1 研究中达到了其主要终点